+1-617-394-8820 contact@baybiosciences.com

Bay Biosciences provides high quality, clinical grade bio-samples, cryogenically preserved biopsy tissue, bone marrow FFPE blocks with matched sera (serum), plasma and peripheral blood mononuclear cells (PBMC) biofluid specimens from patients diagnosed with Acute Myeloid Leukemia (AML) disease.

The sera (serum), plasma and peripheral blood mononuclear cells (PBMC) biofluid samples are processed from patient’s peripheral whole-blood using customized collection and processing protocols. The Acute Myeloid Leukemia (AML) bio-specimens are collected from unique patients diagnosed with Acute Myeloid Leukemia (AML) disease and are provided to a valued pharmaceutical customer for research, development and drug discovery.

Acute Myeloid Leukemia (AML) Overview

Acute Myeloid Leukemia (AML)  which is also known as Acute Myelogenous Leukemia is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and  blood and interfere with normal blood cell production. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection.

As an Acute Leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated. It can sometimes spread to other parts of the body including the lymph nodes, skin, gums, liver, spleen, central nervous system (brain and spinal cord), and testicles. Most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells.

Signs and Symptoms of Acute Myeloid Leukemia (AML) include:

General signs and symptoms of the early stages of Acute Myeloid Leukemia (AML) may mimic those of the flu or other common diseases.

Causes of Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) occurs when a bone marrow cell develops changes (mutations) in its genetic material or DNA (Deoxyribonucleic Acid). A cell’s DNA contains the instructions that tell a cell what to do. Normally, the DNA tells the cell to grow at a set rate and to die at a set time. In Acute Myeloid Leukemia (AML), the mutations tell the bone marrow cell to continue growing and dividing. When this happens, blood cell production becomes out of control. The bone marrow produces immature cells that develop into leukemic white blood cells called myeloblasts. These abnormal cells are unable to function properly, and they can build up and crowd out healthy cells. It is not clear what causes the DNA mutations that lead to leukemia.

Risk Factors of Developing Acute Myeloid Leukemia (AML)

Many patients with AML disease have no known risk factors, and many patients who have risk factors never develop the cancer. Factors that may increase the risk of Acute Myeloid Leukemia (AML) include:

  • Increasing Age: The risk of Acute Myeloid Leukemia (AML) increases with age. Acute Myeloid leukemia is most common in adults age 65 and older.
  • Sex: Men are more likely to develop Acute Myeloid Leukemia (AML) than are women.
  • Previous Cancer Treatment: Patients who have had certain types of chemotherapy and radiation therapy may have a greater risk of developing AML.
  • Exposure to Radiation: Patients exposed to very high levels of radiation, such as survivors of a nuclear reactor accident, have an increased risk of developing AML.
  • Dangerous Chemical Exposure: Exposure to certain chemicals, such as benzene, is linked to a greater risk of AML.
  • Smoking: Acute Myeloid Leukemia (AML) is linked to cigarette smoking, which contains benzene and other known cancer causing chemicals.
  • Other Blood Disorders: Patients who have had another blood disorder, such as myelodysplasia, myelofibrosis, polycythemia vera or thrombocythemia, are at greater risk of developing AML.
  • Genetic Disorders: Certain genetic disorders, such as Down syndrome, are associated with an increased risk of AML.

Detailed clinical data, Lumbar puncture test (Spinal Tap), bone marrow, elevated biomarker levels, genetic information, biopsy, pathology annotations associated with the Acute Myeloid Leukemia (AML) patient’s specimens is provided to a valued customer for research, development and drug discovery.

The Acute Myeloid Leukemia (AML) disease sera (serum), plasma and PBMC biofluid samples are processed from patients peripheral whole-blood using customized collection and processing protocols provided by the researcher.

Bay Biosciences is a global leader in providing researchers with high quality, clinical grade, fully characterized human tissue samples, bio-specimens and human bio-fluid collections from cancer (tumor) tissue, cancer sera (serum), cancer plasma, cancer PBMC and human tissue samples from most other therapeutic areas and diseases.

Bay Biosciences maintains and manages it’s own bio-repository, human tissue bank (biobank) consisting of thousands of diseased samples (specimens) and from normal healthy donors available in all formats and types. Our biobank procures and stores fully consented, deidentified and institutional review boards (IRB) approved human tissue samples and matched controls.

All our human human tissue collections, human specimens and human bio-fluids are provided with detailed samples associated patient’s clinical data. This critical patient’s clinical data includes information relating to their past and current disease, treatment history, lifestyle choices, biomarkers and genetic information. Patient’s data is extremely valuable for researchers and is used to help identify new effective treatments (drug discovery & development) in oncology, other therapeutic areas and diseases. This clinical information is critical to demonstrate their impact, monitor the safety of medicines, testing & diagnostics, and generate new knowledge about the causes of disease and illness. 

Bay Biosciences banks wide variety of human tissue samples and biological samples including cryogenically preserved -80°C, fresh, fresh frozen tissue samplestumor tissue samples, FFPE’s, tissue slides, with matching human bio-fluids, whole blood and blood derived products such as serumplasma and PBMC’s.

Bay Biosciences is a global leader in collecting and providing human tissue samples according to the researchers specified requirements and customized, tailor made collection protocols. Please contact us anytime to discuss your special research projects and customized human tissue sample requirements.

Bay Biosciences provides human tissue samples (human specimens) from diseased and normal healthy donors; including peripheral whole-blood, amniotic fluid, bronchoalveolar lavage fluid (BAL), sputum, pleural effusion, cerebrospinal fluid (CSF), serum (sera), plasma, peripheral blood mononuclear cells (PBMC’s), saliva, Buffy coat, urine, stool samples, aqueous humor, vitreous humor, kidney stones, renal calculi, nephrolithiasis, urolithiasis and other bodily fluids from most diseases including cancer. We can also procure most human bio-specimens and can do special collections and requests of human samples that are difficult to find. All our human tissue samples are procured through IRB approved clinical protocols and procedures. 

In addition to the standard processing protocols Bay Biosciences can also provide human plasmaserum, PBMC bio-fluid samples using custom processing protocols, you can buy donor specific sample collections in higher volumes and specified sample aliquoting from us. Bay Biosciences also provides human samples from normal healthy donors, volunteers, for controls and clinical research, contact us Now.

 

日本のお客様は、ベイバイオサイエンスジャパンBay Biosciences Japan またはhttp://baybiosciences-jp.com/contact/までご連絡ください。